Schultz KD - Search Results

1

Paus R, Heinzelmann T, Schultz KD, Furkert J, Fechner K, Czarnetzki BM. Paus R, et al. Among authors: schultz kd. Lab Invest. 1994 Jul;71(1):134-40. Lab Invest. 1994. PMID: 7518880

2

Determination of substance P in human nasal lavage fluid.

Schultz KD, Furkert J, O'Connor A, Böttcher M, Schmidt M, Baumgarten CR, Kunkel G. Schultz KD, et al. Neuropeptides. 1996 Apr;30(2):117-24. doi: 10.1016/s0143-4179(96)90078-5. Neuropeptides. 1996. PMID: 8771553

3

Gelatin sponge-supported histoculture of human nasal mucosa.

Schierhorn K, Brunnée T, Paus R, Schultz KD, Niehus J, Agha-Mir-Salim P, Kunkel G. Schierhorn K, et al. Among authors: schultz kd. In Vitro Cell Dev Biol Anim. 1995 Mar;31(3):215-20. doi: 10.1007/BF02639436. In Vitro Cell Dev Biol Anim. 1995. PMID: 7538857

4

Substance-P-induced histamine release from human nasal mucosa in vitro.

Schierhorn K, Brunnée T, Schultz KD, Jahnke V, Kunkel G. Schierhorn K, et al. Among authors: schultz kd. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):109-14. doi: 10.1159/000236946. Int Arch Allergy Immunol. 1995. PMID: 7542055

5

Substance P is generated in vivo following nasal challenge of allergic individuals with bradykinin.

Baumgarten CR, O'Connor A, Dokic D, Schultz KD, Kunkel G. Baumgarten CR, et al. Among authors: schultz kd. Clin Exp Allergy. 1997 Nov;27(11):1322-7. Clin Exp Allergy. 1997. PMID: 9420137

6

Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells.

Graf K, Kunkel K, Zhang M, Gräfe M, Schultz K, Schudt C, Biroc S, Fleck E, Kunkel G. Graf K, et al. Peptides. 1995;16(7):1273-8. doi: 10.1016/0196-9781(95)00077-w. Peptides. 1995. PMID: 8545250

7

ELISA for the neuropeptide degrading endopeptidase 3.4.24.11 in human serum and leukocytes.

Zhang M, Niehus J, Schnellbacher T, Müller S, Graf K, Schultz KD, Baumgarten CR, Lucas C, Kunkel G. Zhang M, et al. Among authors: schultz kd. Peptides. 1994;15(5):843-8. doi: 10.1016/0196-9781(94)90040-x. Peptides. 1994. PMID: 7527144

8

Alpha 2- and beta 2-adrenoceptor downregulation in marathon runners.

Schultz KD, Fritschka E, Kribben A, Rothschild M, Thiede HM, Distler A, Philipp T. Schultz KD, et al. J Hypertens Suppl. 1989 Dec;7(6):S48-9. J Hypertens Suppl. 1989. PMID: 2561150

9

Increased forskolin stimulation of lymphocyte-adenylate cyclase in normotensive subjects predisposed to essential hypertension.

Schultz KD, Fritschka E, Pauliks LB, Philipp T, Distler A. Schultz KD, et al. J Hypertens Suppl. 1989 Dec;7(6):S142-3. doi: 10.1097/00004872-198900076-00067. J Hypertens Suppl. 1989. PMID: 2632696

10

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page